Roivant Sciences Ltd. (ROIV)

From the record

Roivant Sciences Ltd.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Roivant Sciences Ltd.'s 6 filed years say what it did: revenue went from $24 million in fiscal 2021 to $8 million in fiscal 2026, down 19.1% a year; it rose in 2 of 5 years; the deepest fall was 85% from fiscal 2022 to fiscal 2026; net income was positive in 1 of 6 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-03-31, Roivant Sciences Ltd.'s diluted share count shrank about 0.9% a year, and dividends and buybacks returned about 33% of its net income over 3 years (its filed statements). Its officers and directors filed 123 sales (31 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-03-31, Roivant Sciences Ltd. lost about 6 cents for every dollar of shareholders' money. Leverage: it owed about 7 cents per dollar of assets, and net share issuance: its share count shrank 4.3% over the year (the filed statements).

From the record

Roivant Sciences Ltd.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2026 ranks in the bottom 41% by size; a net margin of -3629.2% ranks in the bottom 18%; revenue growth of -36% a year over the last 3 filed years ranks in the bottom 14% (its annual reports).

From the record

Roivant Sciences Ltd.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Gline, Matthew (CEO, as filed), filing under that title since 2021-10-01, 5.1 years (bottom 49% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 37%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 12%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Roivant Sciences Ltd.'s room to grow, from the newest filed statements (fiscal 2026): cash of $1.4 billion against no long-term debt tagged leaves 25.1% of its assets as net cash, bottom 47% of its family; cash from operations less capital spending is -9183.5% of revenue (bottom 9%); research spending of 8254.4% of revenue (top 7%) (its annual report).

From the record

Roivant Sciences Ltd.'s growth drivers, from the filed years to fiscal 2026: revenue grew -36% a year over the last three filed years against -19.1% over all 6, slowing (bottom 27% of its family); the newest year grew -71.6% (bottom 9%); research spending grew 14.5% a year (top 32%); capital spending grew -13.5% a year (top 49%) (its annual reports). Roivant Sciences Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Roivant Sciences Ltd.'s newest year against its own record: revenue of $8 million in fiscal 2026 came in 70.4% below the $28 million its prior three years' pace pointed to (bottom 12% of its family); net income of $300 million against a prior three-year average of $1.1 billion (bottom 12%); a net margin of a loss larger than its revenue against more than its whole revenue before (bottom 6%) (its annual reports).